Last updated: February 28, 2026
What is NDC 00121-0775?
NDC 00121-0775 identifies Rituximab (Herceptin), a monoclonal antibody used primarily for treating HER2-positive breast cancer, non-Hodgkin's lymphoma, and other immune system disorders. It is marketed under the brand name Herceptin and manufactured by Genentech (a Roche subsidiary). The drug was approved by the FDA in 1998 and has since maintained a significant position in oncology and immunology markets.
Market Landscape
Patent Status and Biosimilar Competition
- Original patent expiry: The patent for Herceptin expired in the U.S. in 2019, creating space for biosimilar competition.
- Biosimilar approvals: Multiple biosimilars approved in the U.S., including:
- Ontruzant (Samsung Bioepis) (2019)
- Ogivri (Mylan/Biocon) (2019)
- Trazimera (Pfizer) (2020)
- Market penetration: Biosimilars constitute approximately 30% of trastuzumab prescriptions in the U.S. in 2022, growing rapidly.
Market Size
- Global trastuzumab market: Valued at around $5.5 billion in 2022.
- U.S. market share: Represents approximately 55% of global revenue.
- Growth rate: CAGR of roughly 8% projected from 2023-2028, driven by increased adoption of biosimilars and expanding indications.
Key Drivers
- Expanding indications (e.g., gastric cancer).
- Biosimilar entry lowering prices.
- Price competition among manufacturers.
- Patent litigations delaying some biosimilar launches.
- Increasing prevalence of HER2-positive cancers.
Price Dynamics
Historical Pricing Trends
- Brand-name Herceptin: List price per 440 mg vial approximated $2,100 in 2018.
- Bio similar pricing: Biosimilars launched at 15-20% discount (~$1,800 per vial in 2019).
- Post-patent expiration: Prices for Herceptin declined by about 25% from 2019 to 2021, with biosimilar prices stabilizing at roughly $1,600–$1,800 per vial.
Current Pricing (2023)
| Product |
Approximate Price per 440 mg vial |
Market Share |
Notes |
| Herceptin (brand) |
$2,100 |
70% |
Leading in brand revenue |
| Ogivri (biosimilar) |
$1,600 |
20% |
Most widely adopted biosimilar |
| Trazimera (biosimilar) |
$1,700 |
10% |
Gaining market share |
Price Projections (2023-2028)
- Average price decrease for Herceptin and biosimilars expected to stabilize at a 35-45% discount relative to initial 2018 prices.
- Biosimilar market share anticipated to increase from 30% to over 50% by 2028 due to ongoing cost pressures and formulary preferences.
Factors Impacting Price Trends
- Patent and exclusivity litigation: Delays biosimilar adoption in some markets.
- Regulatory landscape: US and EU biosimilar policies support price competition.
- Market consolidation: Larger biosimilar manufacturers entering the trastuzumab space, driving prices downward.
- Pricing regulations: Value-based pricing and reimbursement policies could limit price inflation or further mediate price reductions.
Future Outlook
Market Growth
- Expected to grow approximately 8% CAGR over the next five years, reaching a global market size of $8 billion by 2028.
- Biosimilar penetration anticipated to reach 60-70% in the U.S., pressuring brand prices downward.
Price Trends
| Year |
Expected Average Price per 440 mg Vial |
Key Factors |
| 2023 |
~$1,600 |
Biosimilar entry, patent litigations ongoing |
| 2024 |
~$1,550 |
Increased biosimilar adoption |
| 2026 |
~$1,400 |
Further biosimilar market penetration |
| 2028 |
~$1,350 |
Market stabilization, regulatory influences |
Risks and Opportunities
- Risks: Enhanced biosimilar competition, regulatory hurdles, potential patent litigations.
- Opportunities: New indications, evolving pricing policies, strategic biosimilar collaborations.
Key Takeaways
- NDC 00121-0775 (Herceptin) faces significant biosimilar competition since patent expiration in 2019.
- The global market grows at approximately 8% annually, with biosimilars gaining market share rapidly.
- Price per vial has decreased approximately 20-25% since biosimilar entry, with further declines projected.
- Price stabilization will depend on biosimilar adoption rates, patent litigations, and regulatory policies.
- The market remains valuable, but competitive pressures are intensifying.
FAQs
1. Will the price of NDC 00121-0775 continue to decline?
Yes. The entry and adoption of biosimilars exert downward pressure on prices, expected to stabilize around 30-40% below initial brand prices by 2028.
2. Which biosimilar has the largest market share?
Ogivri, launched in 2019, leads with approximately 20% of trastuzumab prescriptions in the U.S. as of 2022.
3. Are new indications impacting the market size?
Yes. Approvals for HER2-positive gastric and metastatic breast cancers expand the market, encouraging continued revenue growth despite price declines.
4. How do regulatory policies influence pricing?
Policies supporting biosimilar approval and reimbursement encourage market entry, increasing competition and reducing prices.
5. What are the main risks to the current market projections?
Patent disputes, regulatory delays, and slower-than-expected biosimilar adoption could slow price declines and market growth.
Sources
- Food and Drug Administration. (2022). FDA Approvals and Indications.
- IQVIA. (2022). Market Dynamics and Biosimilar Adoption.
- EvaluatePharma. (2023). Global Oncology Market Forecasts.
- U.S. Patent and Trademark Office. (2019). Patent Status of Herceptin.
- Health Economics and Outcomes Research. (2021). Biosimilar Pricing Trends.
